Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Journal: Immunity

Published: 2020-10-13

DOI: 10.1016/j.immuni.2020.09.006

Affiliations: 9

Authors: 36

Go to article
Institutions Share
Centre de Recherche en Cancérologie de Toulouse (CRCT), France 0.38
Institut Universitaire du Cancer de Toulouse (IUCT), France 0.17
QIMR Berghofer Medical Research Institute, Australia 0.17
Physiopathology Center of Toulouse-Purpan (CPTP), France 0.15
Université Libre de Bruxelles (ULB), Belgium 0.08
Mediterranean Centre for Molecular Medicine (C3M), France 0.01
Vienna Center for Rare and Undiagnosed Diseases (CeRUD) / Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), Austria 0.01
Barcelona Supercomputing Center (BSC), Spain 0.01
International Center for Infectiology Research (CIRI), France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER